B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

INSR

MOLECULAR TARGET

insulin receptor

UniProt: P06213NCBI Gene: 364333 compounds

INSR (insulin receptor) is targeted by 33 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting INSR

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1osimertinib5.03152
2lapatinib4.84126
3foretinib4.3476
4tozasertib4.3375
5ceritinib4.1965
6brigatinib3.8144
7neratinib3.6638
8nintedanib3.6136
9tae 6843.4330
10fedratinib3.4029
11entrectinib3.1823
12purvalanola3.1823
13lestaurtinib3.0420
14r 4062.8316
15infigratinib2.7715
16pha 6657522.7114
17kw 24492.6413
18linsitinib2.6413
19ast 4872.5612
20aloisine a2.4010
21bms 7548072.309
22su 0148132.208
23asp 30262.087
24purvalanol b2.087
25Crizotinib1.956
26maleimide1.956
27bastadin 71.956
28pf 038147351.795
29osi 6321.795
30Apigenin 5,7,4'-trihydroxy-flavone,1.393
31myricetin-3-O-galactopyranoside [Supplementary Concept]0.691
32Sorafenib0.691
33sp6001250.691

About INSR as a Drug Target

INSR (insulin receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 33 compounds with documented INSR interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

INSR inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.